Document is current

Article History

Received: 9 October 2024

Accepted: 19 January 2025

First Online: 17 March 2025

Declarations

:

: This retrospective study was carried out in compliance with the declaration of Helsinki and with the data protection regulations of the Bavarian University Hospital Act and was approved after examination by the local Ethics Committee (24-128Br). Due to the retrospective design of the study the need for written approval was waived.

: Not applicable.

: V.B. BMS/Celgene: Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding; Janssen: Research Funding, Honoraria; Novartis: Research Funding, Honoraria; Roche: Consultancy, Research Funding; Takeda: Research Funding.V.L.B. Amgen: Honoraria; Celgene/BMS: Research Funding; Kite/Gilead: Research Funding, Honoraria; Novartis: Honoraria; Pfizer: Honoraria.R.A.B. is Consultant for and has received speaker´s honoraria from Bayer Healthcare (Leverkusen, Germany), Novartis (Nürnberg, Germany) and Eisai GmbH (Frankfurt, Germany) and has received travel expenses from BlueEarth Diagnostics (Oxford, UK).J.J. BeiGene Consultancy, Honoraria; Sobi Honoraria; QuiP Consultancy.W.G.K. BMS: Consultancy, Boehringer Ingelheim: Consultancy, mintMedical: Consultancy, Need, Inc.: Honoraria, Falk Foundation: Honoraria.I.Y. received speaker honoraria from Piramal and consultant fees from ABX-CRO, Blue Earth Diagnostics, and Pentixapharm.A.L.I. Honoraria: TAKEDA, ROCHE, AMGEN, JANSSEN, ABBVIE, FOMF, ILLUMINA, ARS TEMPI; Advisory: BAYER, TAKEDA, JANSSEN, ROCHE, ABBVIE, FIDO:M.E. Honoraria, travel costs and personal fees from Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH; advisory roles for Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS.R.C. Advisory for Janssen-Cilag, Roche, AbbVie, Gilead, Celgene, Astra Zeneca; Honoraria and Travel support from Janssen-Cilag, Roche, Abbvie, Gilead, Novartis, Celgene, Astra Zeneca, and Research funding from Novartis.L.H. Advisory Committees: Sanofi, Janssen-Cilag, Pierre-Fabre; travel support: Amgen, Gilead, Janssen-Cilag.A.M. consultation and/or provided lectures for: Gilead/KITE, Novartis, BMS/Celgene, Miltenyi Biomedicine.scientific advisory board of: Miltenyi Biomedicine, Ixaka, Novartis, BMS/Celgene, Gilead/KITE, Kyverna, Century Therapeutics.M.S. Amgen: Research Funding, Speakers Bureau; Astra Zeneca: Speakers Bureau; Aven Cell: Consultancy, BMS/Celgene: Research Funding, Speakers Bureau; CDR-Life: Consultancy, Kite/Gilead: Research Funding, Speakers Bureau; GSK: Speakers Bureau; Ichnos Sciences: Consultancy; Incyte Biosciences: Consultancy; Janssen: Research Funding, Consultancy, Speakers Bureau; Miltenyi Biotec: Research Funding, Consultancy; Morphosys: Research Funding; Molecular Partners: Consultancy; Novartis: Research Funding, Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Takeda: Research Funding, Consultancy, Speakers Bureau.D.He. AbbVie Deutschland GmbH & Co. KG: Research Funding, AstraZeneca: Research Funding, Bristol-Myers Squibb: Research Funding, GE Healthcare GmbH: Consultancy, GWT-TUD GmbH: Consultancy, Siemens Healthcare GmbH: Consultancy, Incyte Corporation: Research Funding, Janssen-Cilag International NV: Research Funding, Merck KGaA: Research Funding, Merck Sharp & Dohme LLC: Research Funding, Miltenyi Biotec B.V. & Co. KG: Research Funding, Novartis Pharma AG: Research Funding, Pfizer Deutschland GmbH: Research Funding, Philogen S.p.A.: Research Funding, Regeneron Pharmaceuticals, Inc.: Research Funding, Roche Pharma AG: Research Funding, Terumo Europe N.V.: Research Funding, UCB BIOPHARMA SRL: Research Funding, Y-mAbs Therapeutics A/S: Research Funding.F.M. has received research funding by AstraZeneca and Kite/Gilead, was advising AstraZeneca, ArgoBio, BMS, CRISPR Therapeutics, Janssen, Kite/Gilead, Miltenyi, Novartis, Sobi, and received honoraria from AstraZeneca, Abbvie, Beigene, BMS, Janssen, Kite/Gilead, Miltenyi, Novartis, Sobi, Taketa.All other authors declare no conflict of interest.